Is Utah Medical Products, Inc. overvalued or undervalued?

As of 7 July 2025, the valuation grade for Utah Medical Products, Inc. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears undervalued, supported by a P/E ratio of 14, an EV to EBIT of 7.70, and a Price to Book Value of 1.56. In comparison, its peer CareDx, Inc. has a significantly higher P/E ratio of approximately 27.91, while Tactile Systems Technology, Inc. shows an EV to EBITDA of 9.59, further illustrating Utah Medical's relative valuation appeal.
Despite the attractive valuation, Utah Medical's recent stock performance has lagged behind the S&P 500, with a 1-year return of -5.62% compared to the S&P 500's 17.14%. This underperformance over the longer term, particularly a 3-year return of -26.66% versus the S&P 500's 70.41%, may raise concerns among investors, but the current valuation metrics suggest that the stock could be a compelling opportunity.